Immunotherapy has shown promising results in the treatment of certain advanced cancers. It is fast becoming an attractive alternative to current anti-cancer treatments. Specifically, the recent development of adoptive cell transfer immunotherapies using T-cells are being tested widely in animal models and cancer patients. While these therapies have solely focused on T-cells, a novel technology involving both effector T and B-cells was found to significantly improve treatment outcomes in animal cancer models.
In vivo sensitized and in vitro activated B-cells augment T-cell based therapy
The current technology utilizes a combination of T-cells along with effector B-cells, uniquely sourced from tumor draining lymph nodes (TDLN) in mice primed with a specific tumor cell. LPS and anti-CD40 are used to activate these purified cells in vitro, followed by inoculation into tumor bearing mice. This combination treatment not only significantly inhibited development of metastasis compared to a T-cell only therapy, but also greatly augmented other anti-cancer therapies, such as radiation and chemotherapy. The B-cells are thought to show improved targeted killing of tumor cells through production of tumor-specific antibodies as well as interactions involving the Fas/FasL and CXCL12/CXCR4 pathways.
- Novel anti-cancer immunotherapy
- Can be used in concert with other anti-cancer therapies, such as radiation and chemotherapy
- Additional potential applications in treating infectious diseases and neurodegenerative disorders
- Improved efficacy compared to T-cell only based therapies
- Can augment treatment outcomes for other anti-cancer therapies, such as radiation and chemotherapy